Literature DB >> 8539431

An animal model for mania: preliminary results.

R S el-Mallakh1, L T Harrison, R Li, D G Changaris, R S Levy.   

Abstract

1. In human bipolar patients mania and bipolar depression are both characterized by decreased membrane Na,K-AtPase activity. Additionally, digoxin neurotoxicity in patients frequently presents with symptoms of mania or depression. 2. These findings suggest that central nervous system Na,K-ATPase inhibition may play a pathophysiologic role in bipolar illness. 3. The authors tested this hypothesis by administering intracerebroventricular (i.c.v.) ouabain to rats at sublethal doses. The authors then measured behavioral activity as total square crossings in an open field. 4. Motoric activity was significantly increased by i.c.v. administration of 5 microliters of ouabain at 10(-3) M. This preliminary study suggests that i.c.v. ouabain administration may provide a useful animal model of mania that is based on observed biochemical changes in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8539431     DOI: 10.1016/0278-5846(95)00123-d

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  17 in total

Review 1.  Endogenous digitalis-like Na+, K+-ATPase inhibitors, and brain function.

Authors:  D Lichtstein; H Rosen
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

Review 2.  Animal models of bipolar mania: The past, present and future.

Authors:  R W Logan; C A McClung
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

Review 3.  Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement.

Authors:  Todd D Gould; Haim Einat
Journal:  Neurosci Biobehav Rev       Date:  2007-05-31       Impact factor: 8.989

Review 4.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 5.  The pump, the exchanger, and the holy spirit: origins and 40-year evolution of ideas about the ouabain-Na+ pump endocrine system.

Authors:  Mordecai P Blaustein
Journal:  Am J Physiol Cell Physiol       Date:  2017-11-07       Impact factor: 4.249

Review 6.  Predictive animal models of mania: hits, misses and future directions.

Authors:  Jared W Young; Brook L Henry; Mark A Geyer
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Intracerebroventricular administration of ouabain alters synaptic plasticity and dopamine release in rat medial prefrontal cortex.

Authors:  Li Sui; Xiao-Jin Song; Jie Ren; Li-Hua Ju; Yan Wang
Journal:  J Neural Transm (Vienna)       Date:  2013-01-12       Impact factor: 3.575

8.  Evaluation of brain creatine kinase activity in an animal model of mania induced by ouabain.

Authors:  Tiago P Freitas; Giselli Scaini; Cristiane Corrêa; Patricia M Santos; Gabriela K Ferreira; Gislaine T Rezin; Morgana Moretti; Samira S Valvassori; João Quevedo; Emilio L Streck
Journal:  J Neural Transm (Vienna)       Date:  2010-02       Impact factor: 3.575

Review 9.  Modeling mania in preclinical settings: A comprehensive review.

Authors:  Ajaykumar N Sharma; Gabriel R Fries; Juan F Galvez; Samira S Valvassori; Jair C Soares; André F Carvalho; Joao Quevedo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-11-04       Impact factor: 5.067

Review 10.  Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase.

Authors:  Vânia Machado Recart; Luiza Spohr; Mayara Sandrielly Pereira Soares; Karina Pereira Luduvico; Francieli Moro Stefanello; Roselia Maria Spanevello
Journal:  Metab Brain Dis       Date:  2021-07-15       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.